Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 25mcg Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy

NCT03115515
View directory record Official record
Conditions
Pregnancy Related, Thyroid
Interventions
levothyroxine
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

NCT01039675
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
500mcg/25mcg once daily, Placebo once daily
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Chester, South Carolina • Gaffney, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks

NCT07099222
View directory record Official record
Conditions
Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness, Constipation, Duration of Response, Narcotics Consumption, Pain After Surgery
Interventions
Low, non-weight based dose of Dexamethasone and Dexmedetomidine in peripheral nerve blocks, Ropivacaine with low, non weight based Dexamethasone additive
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

NCT01199614
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
open-label PTH(1-84)
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

NCT04155047
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Glyocopyrrolate Inhalation Solution administered by Magnair, Placebo administered by Magnair
Combination Product · Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study of Fluticasone Furoate (FF)

NCT01563029
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate, Fluticasone Propionate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Use of Ketamine for Conscious Sedation in Flexible Bronchoscopy

NCT06181188
View directory record Official record
Conditions
Conscious Sedation, Patient Satisfaction, Ketamine
Interventions
Ketamine, Midazolam, Fentanyl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

Open-label Study of Liothyronine in MS

NCT02506751
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
liothyronine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 58 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Ripening in Premature Rupture of Membranes

NCT02314728
View directory record Official record
Conditions
Pregnancy, Premature Rupture of Membranes, Preterm Premature Rupture of Membranes, Unfavorable Cervix
Interventions
Misoprostol, Oxytocin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
15 Years to 50 Years · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

NCT02119286
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF, VI, UMEC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

NCT01573767
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate 100mcg, Placebo, Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Labor Protocol Study

NCT04004845
View directory record Official record
Conditions
Vaginal Delivery, Labor, Induced; Birth
Interventions
Cytotec, oxytocin, Cervical Foley Balloon
Drug · Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Tonsillectomy Pain Reduction Study

NCT00678379
View directory record Official record
Conditions
Postoperative Pain
Interventions
lidocaine (1%) + bupivacaine (0.5%), Normal saline, Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
3 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

NCT01313637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg, Placebo only
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
24
States / cities
Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00676052
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK233705 12.5mcg, GSK233705 25mcg, GSK233705 50mcg, GSK233705 100mcg, GSK233705 200mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Jasper, Alabama • Glendale, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism

NCT02781844
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
25mcg rhPTH(1-84), 50mcg rhPTH(1-84), 100mcg rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
North Hollywood, California • Indianapolis, Indiana • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Misoprostol Ripening Efficacy With Dilapan

NCT03670836
View directory record Official record
Conditions
Labor Onset and Length Abnormalities, Induced; Birth
Interventions
Dilapan, Misoprostol
Device · Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
New York, New York • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

NCT01573624
View directory record Official record
Conditions
Asthma
Interventions
FF/GSK573719, FF, FF/VI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 2, 2026, 10:17 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Analgesic Techniques on Duration of Spontaneously Laboring Patients

NCT01982838
View directory record Official record
Conditions
Effects of; Anesthesia, in Labor and Delivery, Pregnancy, Prolonged First Stage of Labor
Interventions
Epidural de novo, CSE
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 2, 2026, 10:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

NCT01313676
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol, fluticasone furoate, vilanterol, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
16,568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
506
States / cities
Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 369 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 2, 2026, 10:17 PM EDT